U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13N5O4
Molecular Weight 255.231
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GANCICLOVIR

SMILES

C(C(CO)OCn1cnc2c1[nH]c(=N)nc2O)O

InChI

InChIKey=IRSCQMHQWWYFCW-UHFFFAOYSA-N
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)

HIDE SMILES / InChI

Molecular Formula C9H13N5O4
Molecular Weight 255.231
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.drugs.com/monograph/valganciclovir-hydrochloride.html | http://www.rxlist.com/valcyte-drug/indications-dosage.htm

Ganciclovir is a synthetic acyclic nucleoside analogue of 2'-deoxyguanosine active against cytomegalovirus. Ganciclovir has been shown to be active against cytomegalovirus (CMV) and herpes simplex virus (HSV) in humans. To achieve anti-CMV activity, ganciclovir is phosphorylated first to the monophosphate form by a CMV-encoded (UL97 gene) protein kinase homologue, then to the di- and triphosphate forms by cellular kinases. Ganciclovir triphosphate concentrations may be 100-fold greater in CMV-infected than in uninfected cells, indicating preferential phosphorylation in infected cells. Ganciclovir triphosphate, once formed, persists for days in the CMV-infected cell. Ganciclovir triphosphate is believed to inhibit viral DNA synthesis by (1) competitive inhibition of viral DNA polymerases; and (2) incorporation into viral DNA, resulting in eventual termination of viral DNA elongation. Ganciclovir is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS) and for the treatment of acute herpetic keratitis.

Originator

Curator's Comment:: The first synthesis of ganciclovir was reported by Julien Verheyden and John Martin at Syntex Research in California in 1980 and is marketed as sodium salt (Ganciclovir sodium) under the trade names Cytovene and Cymevene.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P08546
Gene ID: NA
Gene Symbol: UL54
Target Organism: Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5)
0.0800000000000000017 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZIRGAN

Approved Use

ZIRGAN is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Launch Date

813628800000
Primary
CYTOVENE

Approved Use

CYTOVENE-IV is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). CYTOVENE-IV is also indicated for the prevention of CMV disease in transplant recipients at risk for CMV disease.

Launch Date

788054400000
Primary
VALCYTE

Approved Use

VALCYTE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)

Launch Date

985737600000
Primary
VALCYTE

Approved Use

VALCYTE is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk

Launch Date

985737600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.8 mg/L
1 g 3 times / day multiple, oral
dose: 1 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
13.3 μg/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
35.4 mg × h/L
1 g 3 times / day multiple, oral
dose: 1 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
53.8 μg × h/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.2 h
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg 6 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 6 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 6 times / day
Sources:
unhealthy, 37.4
Health Status: unhealthy
Age Group: 37.4
Sources:
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
Health Status: unhealthy
Age Group: 38.6
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (18%)
Thrombocytopenia (4%)
Anemia (severe, 4%)
Renal impairment (4%)
Sources:
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 7.4 years (range: 0.5-16.9 years)
Health Status: unhealthy
Age Group: 7.4 years (range: 0.5-16.9 years)
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (22%)
Sources:
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Other AEs: Fever, Infection...
Other AEs:
Fever (48%)
Infection (13%)
Chills (10%)
Sepsis (15%)
Diarrhea (44%)
Anorexia (14%)
Vomiting (13%)
Leukopenia (41%)
Anemia (25%)
Thrombocytopenia (6%)
Neuropathy (9%)
Sweating (12%)
Pruritus (5%)
Catheter infection (9%)
Catheter sepsis (8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Neutropenia 18%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
Health Status: unhealthy
Age Group: 38.6
Sources:
Renal impairment 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
Health Status: unhealthy
Age Group: 38.6
Sources:
Thrombocytopenia 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
Health Status: unhealthy
Age Group: 38.6
Sources:
Anemia severe, 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
Health Status: unhealthy
Age Group: 38.6
Sources:
Neutropenia 22%
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 7.4 years (range: 0.5-16.9 years)
Health Status: unhealthy
Age Group: 7.4 years (range: 0.5-16.9 years)
Sources:
Chills 10%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Sweating 12%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Infection 13%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Vomiting 13%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Anorexia 14%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Sepsis 15%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Anemia 25%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Leukopenia 41%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Diarrhea 44%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Fever 48%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Pruritus 5%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Thrombocytopenia 6%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Catheter sepsis 8%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Catheter infection 9%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Neuropathy 9%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
1999
Guanosine analogues as anti-herpesvirus agents.
2000 Oct-Dec
Prophylaxis against herpesvirus infections in transplant recipients.
2001
Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer.
2001
Pharmacokinetics of the ganciclovir implant in the silicone-filled eye.
2001
Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector.
2001 Apr
Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.
2001 Apr
Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy.
2001 Apr
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
2001 Apr 1
Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
2001 Apr 15
A time to live, a time to die.
2001 Apr 15
Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells.
2001 Feb
Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy.
2001 Feb
Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis.
2001 Feb
Effect of the complexation with cyclodextrins on the in vitro antiviral activity of ganciclovir against human cytomegalovirus.
2001 Feb
Genetic risks of antiviral nucleoside analogues--a survey.
2001 Feb
Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts.
2001 Feb
Failure of cidofovir to reduce CMV-antigenemia in a child transplanted from a matched unrelated donor.
2001 Feb
Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro.
2001 Feb 15
Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.
2001 Feb 15
Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
2001 Feb 15
A tightly regulated immortalized human fetal hepatocyte cell line to develop a bioartificial liver.
2001 Feb-Mar
Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is Ganciclovir a superior agent to Acyclovir?
2001 Feb-Mar
Preemptive ganciclovir for CMV viremia in liver transplantation.
2001 Feb-Mar
Prophylactic antiviral therapy in CMV high-risk liver transplant recipients.
2001 Feb-Mar
Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis.
2001 Feb-Mar
Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone.
2001 Feb-Mar
CMV in kidney transplants in the tacrolimus-mycophenolate era.
2001 Feb-Mar
Epstein-Barr virus encephalitis in a renal allograft recipient diagnosed by polymerase chain reaction on cerebrospinal fluid and successfully treated with ganciclovir.
2001 Jan
Antiviral drugs in chronic hepatitis B: review and meta-analysis.
2001 Jan
Recurrent disseminated herpes zoster and cytomegalic perianal ulcer: a case report and review of the literature.
2001 Jan
Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and.
2001 Jan
[Gene therapy for colorectal cancer].
2001 Jan
Fatal primary infection due to human herpesvirus 6 variant A in a renal transplant recipient.
2001 Jan 27
Toxic megacolon: remember cytomegalovirus.
2001 Mar
Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient.
2001 Mar
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis.
2001 Mar
Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers.
2001 Mar
The real danger of lamivudine-resistant hepatitis B virus infection in the immunocompromised host.
2001 Mar
High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis.
2001 Mar
Frosted branch angiitis in a child with HIV infection.
2001 Mar
New developments in the management of cytomegalovirus infection and disease after renal transplantation.
2001 Mar
Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
2001 Mar 1
Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells.
2001 Mar 1
Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif.
2001 Mar 15
Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.
2001 Mar-Apr
Reactivity of valganciclovir in aqueous solution.
2005 Oct
The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
2017 Mar
A 42-Year-Old Woman With Anemia, Shock, and Ischemic Stroke After Lung Transplantation.
2017 Mar
Top 1% of Inpatients Administered Antimicrobial Agents Comprising 50% of Expenditures: A Descriptive Study and Opportunities for Stewardship Intervention.
2017 Mar
Patents
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:51 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:51 UTC 2021
Record UNII
P9G3CKZ4P5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GANCICLOVIR
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
BW 759U
Code English
GANCICLOVIR [HSDB]
Common Name English
GANCICLOVIR [EP]
Common Name English
GANCICLOVIR [WHO-DD]
Common Name English
GANCICLOVIR [EMA EPAR]
Common Name English
9-((2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY)METHYL)GUANINE
Systematic Name English
GANCICLOVIR [USAN]
Common Name English
GANCICLOVIR [USP MONOGRAPH]
Common Name English
6H-PURIN-6-ONE, 2-AMINO-1,9-DIHYDRO-9-((2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY)METHYL)-
Systematic Name English
GANCICLOVIR [MART.]
Common Name English
VITRASERT
Brand Name English
VALGANCICLOVIR HYDROCHLORIDE IMPURITY A [USP]
Common Name English
ZIRGAN
Brand Name English
GANCICLOVIR [ORANGE BOOK]
Common Name English
RS-21592
Code English
BW-759U
Code English
GANCICLOVIR [INN]
Common Name English
GANCICLOVIR [EP MONOGRAPH]
Common Name English
GANCICLOVIR [VANDF]
Common Name English
NSC-759656
Code English
GANCICLOVIR [MI]
Common Name English
GANCICLOVIR [USP-RS]
Common Name English
GANCICLOVIR [JAN]
Common Name English
GANCYCLOVIR
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 237607
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NCI_THESAURUS C1556
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NCI_THESAURUS C29575
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
EMA ASSESSMENT REPORTS VITRASERT IMPLANT (WITHDRAWN: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NDF-RT N0000020060
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
LIVERTOX 449
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NDF-RT N0000175461
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
EMA ASSESSMENT REPORTS VITRASERT IMPLANT (WITHDRAWN: CYTOMEGALOVIRUS RETINITIS)
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NDF-RT N0000175466
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
WHO-VATC QS01AD09
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
FDA ORPHAN DRUG 5885
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NCI_THESAURUS C281
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
WHO-ATC J05AB06
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
WHO-VATC QJ05AB06
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
WHO-ATC S01AD09
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
FDA ORPHAN DRUG 86494
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
Code System Code Type Description
EVMPD
SUB07881MIG
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
PUBCHEM
135398740
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
DRUG CENTRAL
1277
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
USP_CATALOG
1288306
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY USP-RS
EPA CompTox
82410-32-0
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
DRUG BANK
DB01004
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
NCI_THESAURUS
C517
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
ChEMBL
CHEMBL182
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
RXCUI
4678
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY RxNorm
LACTMED
Ganciclovir
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
INN
6023
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
MERCK INDEX
M5663
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY Merck Index
FDA UNII
P9G3CKZ4P5
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
HSDB
6512
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
CAS
82410-32-0
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
MESH
D015774
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
WIKIPEDIA
GANCICLOVIR
Created by admin on Fri Jun 25 21:02:51 UTC 2021 , Edited by admin on Fri Jun 25 21:02:51 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
Vmax
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TRANSPORTER -> SUBSTRATE
Km
TRANSPORTER -> SUBSTRATE
Vmax
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Km
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY